Advanced Biomed Inc. Common Stock (ADVB)vsWaters Corporation (WAT)
ADVB
Advanced Biomed Inc. Common Stock
$2.64
-11.41%
HEALTHCARE · Cap: $6.58M
WAT
Waters Corporation
$480.07
+0.67%
HEALTHCARE · Cap: $47.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 3638482% more annual revenue ($4.64B vs $127,640). ADVB leads profitability with a 5231.0% profit margin vs 3.6%. WAT earns a higher WallStSmart Score of 43/100 (D).
ADVB
Avoid30
out of 100
Grade: F
WAT
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADVB.
Margin of Safety
-44.6%
Fair Value
$227.71
Current Price
$480.07
$252.36 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 5231 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Revenue surging 113.4% year-over-year
Safe zone — low bankruptcy risk
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
ROE of 1.1% — below average capital efficiency
3.6% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ADVB
The strongest argument for ADVB centers on Price/Book, Profit Margin, Debt/Equity. Profitability is solid with margins at 5231.0% and operating margin at -3856.0%.
Bull Case : WAT
The strongest argument for WAT centers on Revenue Growth, Altman Z-Score. Revenue growth of 113.4% demonstrates continued momentum.
Bear Case : ADVB
The primary concerns for ADVB are Revenue Growth, EPS Growth, Market Cap.
Bear Case : WAT
The primary concerns for WAT are PEG Ratio, Return on Equity, Profit Margin. A P/E of 121.5x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
ADVB profiles as a value stock while WAT is a hypergrowth play — different risk/reward profiles.
WAT is growing revenue faster at 113.4% — sustainability is the question.
WAT generates stronger free cash flow (153M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
WAT scores higher overall (43/100 vs 30/100) and 113.4% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Advanced Biomed Inc. Common Stock
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. The company is headquartered in New York, New York.
Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?